Division of Hematology and Oncology

The study team included, from left, Paula Gonzalez-Ericsson, MD, Xiaopeng Sun, Justin Balko, PharmD, PhD, and Brandie Taylor, MS. (photo by Donn Jones)
October 4, 2023

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

By Tom Wilemon
Houra Merrikh and Juan Carvajal-Garcia, PhD, are studying how to prevent cancer therapy resistance. (photo by Erin O. Smith)
September 1, 2023

Foundation funds research to block drug resistance in cancer treatment

The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance.

By Tom Wilemon
August 10, 2023

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.

By Tom Wilemon
August 8, 2023

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

By Tom Wilemon
Mary Philip, MD, PhD, left, and Michael Rudloff, PhD, found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. (photo by Anthony Czelusniak)
August 3, 2023

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

By Leigh MacMillan
June 15, 2023

New treatment option for metastatic colorectal cancer prolongs survival

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

By Tom Wilemon
May 31, 2023

Liquid biopsy test may detect early-stage and low DNA-shedding cancers

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.
By Tom Wilemon
May 11, 2023

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.
By Tom Wilemon
April 18, 2023

Vanderbilt mourns loss of former Hematology leader Krantz

Sanford Krantz, MD, internationally recognized authority on hematology and erythropoietin and professor of Medicine, Emeritus, died April 13 at his home. He was 89.
By VUMC News and Communications
April 6, 2023

National Cancer Institute honors Berlin’s contributions, leadership

Vanderbilt's Jordan Berlin, MD, is a 2022 recipient of the National Cancer Institute Director’s Award.
By Tom Wilemon
March 30, 2023

New treatment helps mitigate hair loss for chemotherapy patients

Vanderbilt-Ingram Cancer Center has started offering scalp cooling, which mitigates hair loss for patients receiving certain chemotherapy regimens.
By Tom Wilemon
March 30, 2023

VUMC researcher selected for Global Scholars Program

Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.
By Leigh MacMillan
March 16, 2023

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.
By Leigh MacMillan
1 2 3 4 … 13